Journal
ONCOTARGET
Volume 7, Issue 8, Pages 9288-9295Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7063
Keywords
small cell lung cancer; SCLC; molecular imaging; CXCR4; PET
Categories
Funding
- German Research Foundation (DFG)
- University of Wurzburg
Ask authors/readers for more resources
Chemokine receptor CXCR4 is a key factor for tumor growth and metastasis in several types of human cancer. This study investigated the feasibility of CXCR4-directed imaging of small cell lung cancer (SCLC) with positron emission tomography/computed tomography (PET/CT) using the radiolabelled chemokine ligand [Ga-68] Pentixafor. 10 patients with primarily diagnosed (n=3) or pre-treated (n=7) SCLC (n=9) or large cell neuroendocrine carcinoma of the lung (LCNEC, n=1) underwent [Ga-68]Pentixafor-PET/CT. 2-[F-18]fluoro-2-deoxy-D-glucose ([F-18]FDG, n=6) and/or somatostatin receptor (SSTR)-directed PET/CT with [Ga-68] DOTATOC (n=5) and immunohistochemistry (n=10) served as standards of reference. CXCR4-PET was positive in 8/10 patients and revealed more lesions with significantly higher tumor-to-background ratios than SSTR-PET. Two patients who were positive on [F-18]FDG-PET were missed by CXCR4-PET, in the remainder [Ga-68] Pentixafor detected an equal (n=2) or higher (n=2) number of lesions. CXCR4 expression of tumor lesions could be confirmed by immunohistochemistry. Non-invasive imaging of CXCR4 expression in SCLC is feasible. [Ga-68] Pentixafor as a novel PET tracer might serve as readout for confirmation of CXCR4 expression as prerequisite for potential CXCR4-directed treatment including receptor-radio(drug) peptide therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available